Hennion & Walsh Asset Management Inc. Makes New Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 74,827 shares of the specialty pharmaceutical company’s stock, valued at approximately $634,000. Hennion & Walsh Asset Management Inc. owned approximately 0.15% of KalVista Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of KALV. Vestal Point Capital LP lifted its holdings in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares during the period. Great Point Partners LLC bought a new position in shares of KalVista Pharmaceuticals during the second quarter valued at $15,768,000. State Street Corp lifted its holdings in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the period. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after acquiring an additional 192,091 shares during the period. Finally, Readystate Asset Management LP bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $2,084,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KALV. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $25.00.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at $2,677,311. This trade represents a 2.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock worth $304,086 over the last three months. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Stock Up 0.6 %

Shares of KALV stock opened at $8.30 on Tuesday. The stock has a 50-day moving average price of $9.00 and a 200 day moving average price of $11.13. The firm has a market cap of $410.17 million, a price-to-earnings ratio of -2.28 and a beta of 0.86. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.88.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).